Retour aux actualités
Remote patient monitoring: Sêmeia raises €21M and opens a new chapter
Actualités
Founded nearly 10 years ago, the Toulouse-based company Sêmeia has established itself as a key player in remote patient monitoring in France.
Having achieved profitability and large-scale deployment of remote monitoring in nephrology, Sêmeia is now strengthening its capabilities to:
A look back at a journey, clinical results, and a fundraising round that opens a new chapter.
In 2017, Pierre Hornus, Daniel Szeftel, and Mathieu Godart founded Sêmeia, a company dedicated to the collection and intelligent processing of patient health data.
Their objective? To simplify the daily work of health professionals and improve patient monitoring.
The three founders are convinced that solutions such as medical remote monitoring — still in its infancy in France at the time — can provide answers to public health challenges. With the growing prevalence of chronic diseases—16 million patients and 75% of healthcare spending by 2035 — the multiplication of health data, care pathways becoming more complex, and medical time for care teams shrinking, the healthcare system needs innovations to streamline and strengthen the daily management of chronic patients.
Nearly ten years later, remote monitoring has entered common practice and benefits from reimbursement by the national health insurance system. Sêmeia, thanks to MedicWise, its solution, has become the reference solution for medical remote patient monitoring in France. It is now widely deployed across the country, with more than 500 care teams using it and 35,000 patients monitored across five therapeutic areas: nephrology, organ transplantation, mental health, and cardiology.
MedicWise, the CE-marked Class IIa medical device developed by Sêmeia, is continuously evolving to offer a useful and intuitive solution for care teams, for the benefit of patients with chronic conditions.
Its multi-pathology positioning makes it a unique player in the remote patient monitoring market, with a strong ability to rapidly expand into new therapeutic areas, while also enabling simplified and enhanced coordinated monitoring for patients suffering from multiple chronic conditions.
Designed in close collaboration with medical teams and patients, and relying on a strong expertise in health data management, MedicWise automatically collects, structures, and returns patient health data: lab results, physiological parameters, patient-reported outcomes, passive data, disease activity scores, etc.
Complex alerts are triggered according to patient profiles and care team expectations, enabling care to be adapted as quickly and as closely as possible.
To reduce data entry burden, improve information flow, and simplify care team organization, MedicWise integrates with existing healthcare information systems through multiple interoperability streams.
Highly aware of the importance of health data protection, Sêmeia has always been actively committed to ensuring the highest level of security, confidentiality, and transparency: data is hosted in France by a sovereign HDS-certified provider, and all subcontractors are hosted in France and Europe.
Historically present in nephrology, Sêmeia is now considered the leader in this specialty, where clinical and organizational results have already been demonstrated: a 26% reduction in patients’ hospitalizations and a 73% reduction in physicians’ time.
With several years of patients’ follow-up in different pathologies, Sêmeia has demonstrated significant results benefiting both patients and caregivers.
Strengthened by strong patient and care team adoption of its remote monitoring solution, these results demonstrate the value of MedicWise offered by Sêmeia in the daily patient follow-up. This paves the way for large-scale deployment.
This impact is particularly highlighted by Flora Velle-Bonvouloir, Director Growth & Expansion, Citizen Capital: “Sêmeia goes beyond improving patient monitoring: it provides healthcare professionals with enhanced medical decision support and aims to generate significant organizational and economic benefits for the healthcare system. It delivers multiple levels of impact, and that is precisely what we at Citizen Capital seek to support.”
High standards are at the core of Sêmeia activity, both in its operations and in the services it provides.
Driven by this DNA, Sêmeia has chosen a growth trajectory that is both ambitious and controlled. Now profitable, the company continues to invest in expanding remote monitoring to new patient populations and leveraging cutting-edge technologies. This positioning strengthens the robustness of its model and its ability to sustain itself over time.
This execution capability is also reflected in its external growth strategy. With two acquisitions completed—Optim’Care in 2022 and Healabs in 2025—Sêmeia has strengthened its expertise and consolidated its market position.
Behind this trajectory lies a solid operational base: a team of 70 employees, deep sector expertise, low turnover, and a constant commitment to innovation—a key factor in a sector where credibility relies as much on technology as on the quality of relationships with healthcare institutions and professionals.
Innovation is a key driver in Sêmeia’s daily activity. Its DataLab, composed of data scientists, is a case in point. Specialized in health data and advanced analytical models using the latest AI technologies, it develops predictive models as well as innovative features useful for care and research project management.
Involved in fifteen medical studies alongside care teams, Sêmeia provides daily expertise in data structuring and analysis, as well as in the design and management of ambitious projects.
Sêmeia’s commitment to the healthcare system is also illustrated by the fact that nearly a third of patients monitored by Sêmeia live in medical deserts, demonstrating the solution’s direct contribution to reducing territorial inequalities in access to care.
“Sêmeia has built a particularly strong profile, combining strong regional roots, tangible impact, and economic sustainability. Its ability to contribute to structuring an emerging market while remaining true to its mission makes it a strategic player we are determined to support over the long term.” Marion Eymar, Investment Director, Healthcare, Banque des Territoires
These strengths have also contributed to the decision of new investors to support Sêmeia:
“Sêmeia combines what rarely goes together in healthtech: clinical evidence, large-scale adoption, and profitability. Supporting Pierre and his team naturally fits with our impact thesis: supporting companies that create measurable value for patients, clinicians, and the healthcare system.” Nadja Bresous Mehigan, Partner Impact, XAnge
Thanks to this new funding, Sêmeia intends to strengthen its position at the heart of the healthcare system through three main development areas:
Support the successful rollout of telemonitoring for new pathologies.
Sêmeia plans to launch new medical studies with the support of clinical experts to validate the positive impact of remote monitoring in new conditions ahead of their market entry.
Depression, type 2 diabetes, inflammatory bowel disease, and chronic liver diseases — new clinical studies are already underway or in preparation.
The ambition is also to extend remote monitoring to general practitioners, key players in care management, as 20% of their patients live with a chronic disease.
Strengthen investments in data-driven innovation through AI technologies for care and research.
Semeia is committed to integrating new AI-driven features to enhance software performance continuously and optimise the organisation of medical follow-up: predictive models, weak signal detection, and automation of administrative tasks.
This effort will also support the company’s contribution to clinical research projects conducted in partnership with clinical teams.
Confirm its position as a key player in the telemedicine market through partnerships and targeted acquisitions.
Sêmeia has actively contributed to structuring the remote monitoring market in France through strategic acquisitions (Optim’Care in 2022 and Healabs in 2025) and by forming key partnerships with major digital health players such as Cureety.
The company intends to pursue its strategy of partnerships and selective acquisitions to enrich the user experience and further integrate digital solutions into care pathways.
New discussions are already underway.
This fundraising brings together investors who are recognised for their commitment to technological innovation and impact-driven companies. These include the German fund Acton Capital, and French impact investment funds, Mutuelles Impact (a fund initiated by Mutualité Française and managed by XAnge in partnership with Impactivist), and Citizen Capital.
Historical investors, Banque des Territoires (Groupe Caisse des Dépôts) – for which the operation fully aligns with the implementation of the "Santé et Grand âge" roadmap of the Caisse des Dépôts Group, committing €25 billion over 5 years - and Orange Ventures, have also renewed their commitment alongside Sêmeia.
“We are very pleased to actively participate in Sêmeia’s development and support its ambition to deliver high-impact digital health services. By leveraging cutting-edge technologies, Sêmeia supports healthcare professionals and patients on a daily basis towards better care, while contributing to the efficiency and sustainability of the healthcare system.”
Sebastian Wossagk, Managing Partner, Acton Capital
“Sêmeia has demonstrated its ability to execute and structure its market while building a solid model. This reinvestment naturally reflects our commitment to supporting impact-driven players over the long term.” Mathieu de La Rochefoucauld, President and Managing Partner, Orange Ventures.
Having demonstrated its ability to establish a strong presence in France and build a new market, Sêmeia intends to build on this momentum with a clear commitment to accelerating its growth: expanding its applications to new conditions, developing new uses through emerging technologies, and actively helping to shape a rapidly evolving market.
And all this while remaining true to Sêmeia’s core mission: to improve access to care, strengthen prevention, and support research, for the benefit of healthcare professionals and patients.
With this new round of funding, investors are backing this long-term ambition: to make remote patient monitoring a standard practice in care delivery, for the benefit of the entire healthcare system.
1 50% des patients chroniques sont atteints de plusieurs maladies chroniques.
2 Christophe Mariat, Miriana Dinic, Damien Thibaudin, Nicolas Maillard, #2096 A randomized controlled study of telemonitoring in kidney transplantation: interim results of the Ap'TX trial, Nephrology Dialysis Transplantation, Volume 39, Issue Supplement_1, May 2024, gfae069–0092–2096, https://doi.org/10.1093/ndt/gfae069.092
